Agilon Health, Inc. (NYSE:AGL) Given Average Recommendation of “Hold” by Analysts

Shares of Agilon Health, Inc. (NYSE:AGL) have received a consensus rating of “Hold” from the sixteen analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $2.1750.

Several analysts have recently commented on the company. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Citigroup dropped their target price on shares of Agilon Health from $0.85 to $0.75 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. Barclays cut their price target on shares of Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a report on Friday, February 27th. Finally, Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Agilon Health in the 2nd quarter valued at approximately $31,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Agilon Health during the third quarter worth $26,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health during the third quarter worth $34,000. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Agilon Health in the third quarter worth $37,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Agilon Health by 214.0% in the second quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after purchasing an additional 25,270 shares in the last quarter.

Agilon Health Trading Down 18.7%

NYSE AGL opened at $0.48 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. Agilon Health has a 52 week low of $0.34 and a 52 week high of $6.08. The business has a 50 day moving average price of $0.68 and a 200-day moving average price of $0.80. The company has a market cap of $199.14 million, a price-to-earnings ratio of -0.51 and a beta of 0.11.

Agilon Health shares are set to reverse split on Tuesday, March 31st. The 1-25 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, March 30th.

Agilon Health (NYSE:AGL) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative net margin of 6.60% and a negative return on equity of 120.82%. The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.46 billion. As a group, equities analysts expect that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.